'US FDA panel backs Replimune skin cancer drug study data'- Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-replimune-skin-cancer-drug-study-data-2026-07-30/
A group of government experts said Replimune's skin cancer medicine showed real results in tests, which is a good sign for the company. When experts approve study results like this, it means the medicine might be one step closer to helping patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.